2023-04-17 16:05:00 ET
Shares of CRISPR Therapeutics (NASDAQ: CRSP) are enjoying another strong session Monday. Specifically, the gene-editing company's stock was up by a healthy 7.26% on exceptionally heavy volume as of 2:02 p.m. ET Monday afternoon.
CRISPR's shares have been steadily moving higher since the Institute for Clinical and Economic Review (ICER), a U.S drug-pricing group, stated in a draft report that its Vertex Pharmaceuticals 's (NASDAQ: VRTX) partnered sickle cell treatment, exa-cel, would be cost effective if priced below $1.9 million.
Specifically, ICER issued the draft report last Thursday, and since then, CRISPR's stock has gapped up by a noteworthy 24.6%.
For further details see:
Why CRISPR Therapeutics Stock Is Marching Higher Today